Integrity of the LXXLL motif in Stat6 is required for the inhibition of breast cancer cell growth and enhancement of differentiation in the context of progesterone

详细信息    查看全文

• 作者：Min Wei (1) (2)
  Qi He (1)
  Zhongyin Yang (2)
  Zhiwei Wang (1) (2)
  Qing Zhang (2)
  Bingya Liu (2)
  Qinlong Gu (2)
  Liping Su (2)
  Yingyan Yu (2)
  Zhenggang Zhu (2)
  Guofeng Zhang (3)
  
  1. Breast Department ; International Peace Maternity and Child Health Hospital ; Shanghai Jiaotong University ; Shanghai ; 200030 ; People鈥檚 Republic of China
  2. Key Laboratory of Shanghai Gastric Neoplasms ; Department of Surgery ; Shanghai Institute of Digestive Surgery ; Ruijin Hospital ; School of Medicine ; Shanghai Jiao Tong University ; Shanghai ; 200025 ; People鈥檚 Republic of China
  3. Department of General Surgery ; Tongji Hospital ; Tongji University School of Medicine ; Shanghai ; 200025 ; People鈥檚 Republic of China
  
• 关键词：Breast cancer ; Stat6 ; p21 ; p27
• 刊名：BMC Cancer
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：14
• 期：1
• 全文大小：1,900 KB
• 参考文献：1. Foulkes, WD, Smith, IE, Reis-Filho, JS (2010) Triple-negative breast cancer. N Engl J Med 363: pp. 1938-1948 CrossRef
  2. Schneider, MR, Michna, H, Nishino, Y, el Etreby, MF (1990) Antitumor activity and mechanism of action of different antiprogestins in experimental breast cancer models. J Steroid Biochem Mol Biol 37: pp. 783-787 CrossRef
  3. Ismail, PM, DeMayo, FJ, Amato, P, Lydon, JP (2004) Progesterone induction of calcitonin expression in the murine mammary gland. J Endocrinol 180: pp. 287-295 CrossRef
  4. Conneely, OM, Mulac-Jericevic, B, Arnett-Mansfield, R (2007) Progesterone signaling in mammary gland development. Ernst Schering Found Symp Proc 1: pp. 45-54
  5. Conneely, OM, Jericevic, BM, Lydon, JP (2003) Progesterone receptors in mammary gland development and tumorigenesis. J Mammary Gland Biol Neoplasia 8: pp. 205-214 CrossRef
  6. Shyamala, G, Yang, X, Cardiff, RD, Dale, E (2000) Impact of progesterone receptor on cell-fate decisions during mammary gland development. Proc Natl Acad Sci U S A 97: pp. 3044-3049 CrossRef
  7. Ramamoorthy, S, Dhananjayan, SC, Demayo, FJ, Nawaz, Z (2010) Isoform-specific degradation of PR-B by E6-AP is critical for normal mammary gland development. Mol Endocrinol 24: pp. 2099-2113 CrossRef
  8. Brisken, C, O鈥橫alley, B (2010) Hormone action in the mammary gland. Cold Spring Harb Perspect Biol 2: pp. a003178 CrossRef
  9. Stingl, J (2011) Estrogen and progesterone in normal mammary gland development and in cancer. Horm Cancer 2: pp. 85-90 CrossRef
  10. Medina, D, Kittrell, FS, Tsimelzon, A, Fuqua, SA (2007) Inhibition of mammary tumorigenesis by estrogen and progesterone in genetically engineered mice. Ernst Schering Found Symp Proc 1: pp. 109-126
  11. Botella, J, Duranti, E, Duc, I, Cognet, AM, Delansorne, R, Paris, J (1994) Inhibition by nomegestrol acetate and other synthetic progestins on proliferation and progesterone receptor content of T47-D human breast cancer cells. J Steroid Biochem Mol Biol 50: pp. 41-47 CrossRef
  12. Schoonen, WG, Joosten, JW, Kloosterboer, HJ (1995) Effects of two classes of progestagens, pregnane and 19-nortestosterone derivatives, on cell growth of human breast tumor cells: II. T47D cell lines. J Steroid Biochem Mol Biol 55: pp. 439-444 CrossRef
  13. Sutherland, RL, Hall, RE, Pang, GY, Musgrove, EA, Clarke, CL (1988) Effect of medroxyprogesterone acetate on proliferation and cell cycle kinetics of human mammary carcinoma cells. Cancer Res 48: pp. 5084-5091
  14. Chen, B, Pan, H, Zhu, L, Deng, Y, Pollard, JW (2005) Progesterone inhibits the estrogen-induced phosphoinositide 3-kinase鈥撯€?鈥堿KT鈥撯€?鈥塆SK-3beta鈥撯€?鈥塩yclin D1鈥撯€?鈥塸RB pathway to block uterine epithelial cell proliferation. Mol Endocrinol 19: pp. 1978-1990 CrossRef
  15. Musgrove, EA, Swarbrick, A, Lee, CS, Cornish, AL, Sutherland, RL (1998) Mechanisms of cyclin-dependent kinase inactivation by progestins. Mol Cell Biol 18: pp. 1812-1825
  16. Groshong, SD, Owen, GI, Grimison, B, Schauer, IE, Todd, MC, Langan, TA, Sclafani, RA, Lange, CA, Horwitz, KB (1997) Biphasic regulation of breast cancer cell growth by progesterone: role of the cyclin-dependent kinase inhibitors, p21 and p27(Kip1). Mol Endocrinol 11: pp. 1593-1607 CrossRef
  17. Musgrove, EA, Lee, CS, Cornish, AL, Swarbrick, A, Sutherland, RL (1997) Antiprogestin inhibition of cell cycle progression in T-47D breast cancer cells is accompanied by induction of the cyclin-dependent kinase inhibitor p21. Mol Endocrinol 11: pp. 54-66 CrossRef
  18. Eigeliene, N, Harkonen, P, Erkkola, R (2008) Effects of estradiol and medroxyprogesterone acetate on expression of the cell cycle proteins cyclin D1, p21 and p27 in cultured human breast tissues. Cell Cycle 7: pp. 71-80 CrossRef
  19. Gizard, F, Robillard, R, Gervois, P, Faucompre, A, Revillion, F, Peyrat, JP, Hum, WD, Staels, B (2005) Progesterone inhibits human breast cancer cell growth through transcriptional upregulation of the cyclin-dependent kinase inhibitor p27Kip1 gene. FEBS Lett 579: pp. 5535-5541 CrossRef
  20. Swarbrick, A, Lee, CS, Sutherland, RL, Musgrove, EA (2000) Cooperation of p27(Kip1) and p18(INK4c) in progestin-mediated cell cycle arrest in T-47D breast cancer cells. Mol Cell Biol 20: pp. 2581-2591 CrossRef
  21. Owen, GI, Richer, JK, Tung, L, Takimoto, G, Horwitz, KB (1998) Progesterone regulates transcription of the p21(WAF1) cyclin- dependent kinase inhibitor gene through Sp1 and CBP/p300. J Biol Chem 273: pp. 10696-10701 CrossRef
  22. Wang, J, Hu, Y, Nekvindova, J, Ingelman-Sundberg, M, Neve, EP (2010) IL-4-mediated transcriptional regulation of human CYP2E1 by two independent signaling pathways. Biochem Pharmacol 80: pp. 1592-1600 CrossRef
  23. Simard, J, Ricketts, ML, Gingras, S, Soucy, P, Feltus, FA, Melner, MH (2005) Molecular biology of the 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase gene family. Endocr Rev 26: pp. 525-582 CrossRef
  24. Minami, S, Ohtani-Fujita, N, Igata, E, Tamaki, T, Sakai, T (1997) Molecular cloning and characterization of the human p27Kip1 gene promoter. FEBS Lett 411: pp. 1-6 CrossRef
  25. Pang, H, Rowan, BG, Al-Dhaheri, M, Faber, LE (2004) Epidermal growth factor suppresses induction by progestin of the adhesion protein desmoplakin in T47D breast cancer cells. Breast Cancer Res 6: pp. R239-R245 CrossRef
  26. Qu, Y, Li, JF, Cai, Q, Wang, YW, Gu, QL, Zhu, ZG, Liu, BY (2008) Over-expression of FRZB in gastric cancer cell suppresses proliferation and induces differentiation. J Cancer Res Clin Oncol 134: pp. 353-364 CrossRef
  27. Gizard, F, Amant, C, Barbier, O, Bellosta, S, Robillard, R, Percevault, F, Sevestre, H, Krimpenfort, P, Corsini, A, Rochette, J (2005) PPAR alpha inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a. J Clin Invest 115: pp. 3228-3238 CrossRef
  28. Wei, M, Liu, B, Su, L, Li, J, Zhang, J, Yu, Y, Yan, M, Yang, Z, Chen, X, Liu, J (2010) A novel plant homeodomain finger 10-mediated antiapoptotic mechanism involving repression of caspase-3 in gastric cancer cells. Mol Cancer Ther 9: pp. 1764-1774 CrossRef
  29. Carnevalli, LS, Masuda, K, Frigerio, F, Le Bacquer, O, Um, SH, Gandin, V, Topisirovic, I, Sonenberg, N, Thomas, G, Kozma, SC (2010) S6K1 plays a critical role in early adipocyte differentiation. Dev Cell 18: pp. 763-774 CrossRef
  30. Dubey, R, Chhabra, R, Saini, N (2011) Small interfering RNA against transcription factor STAT6 leads to increased cholesterol synthesis in lung cancer cell lines. PLoS One 6: pp. e28509 CrossRef
  31. Wei, M, Wang, ZW, Yao, HL, Yang, ZY, Zhang, Q, Liu, BY, Yu, YY, Su, LP, Zhu, ZG, Gu, QL (2011) P27(Kip1), regulated by glycogen synthase kinase-3beta, results in HMBA-induced differentiation of human gastric cancer cells. BMC Cancer 11: pp. 109 CrossRef
  32. Chien, WW, Domenech, C, Catallo, R, Salles, G, Ffrench, M (2010) S-phase lengthening induced by p16(INK4a) overexpression in malignant cells with wild-type pRb and p53. Cell Cycle.
  33. Graham, ML, Dalquist, KE, Horwitz, KB (1989) Simultaneous measurement of progesterone receptors and DNA indices by flow cytometry: analysis of breast cancer cell mixtures and genetic instability of the T47D line. Cancer Res 49: pp. 3943-3949
  34. Graham, ML, Bunn, PA, Jewett, PB, Gonzalez-Aller, C, Horwitz, KB (1989) Simultaneous measurement of progesterone receptors and DNA indices by flow cytometry: characterization of an assay in breast cancer cell lines. Cancer Res 49: pp. 3934-3942
  35. Wei, M, Liu, B, Gu, Q, Su, L, Yu, Y, Zhu, Z (2012) Stat6 cooperates with Sp1 in controlling breast cancer cell proliferation by modulating the expression of p21(Cip1/WAF1) and p27 (Kip1). Cell Oncol (Dordr) 36: pp. 79-93 CrossRef
  36. Liu, Z, Wong, J, Tsai, SY, Tsai, MJ, O鈥橫alley, BW (2001) Sequential recruitment of steroid receptor coactivator-1 (SRC-1) and p300 enhances progesterone receptor-dependent initiation and reinitiation of transcription from chromatin. Proc Natl Acad Sci U S A 98: pp. 12426-12431 CrossRef
  37. Rowan, BG, Garrison, N, Weigel, NL, O鈥橫alley, BW (2000) 8-Bromo-cyclic AMP induces phosphorylation of two sites in SRC-1 that facilitate ligand-independent activation of the chicken progesterone receptor and are critical for functional cooperation between SRC-1 and CREB binding protein. Mol Cell Biol 20: pp. 8720-8730 CrossRef
  38. Arpa, L, Valledor, AF, Lloberas, J, Celada, A (2009) IL-4 blocks M-CSF-dependent macrophage proliferation by inducing p21Waf1 in a STAT6-dependent way. Eur J Immunol 39: pp. 514-526 CrossRef
  39. Sumida, T, Itahana, Y, Hamakawa, H, Desprez, PY (2004) Reduction of human metastatic breast cancer cell aggressiveness on introduction of either form a or B of the progesterone receptor and then treatment with progestins. Cancer Res 64: pp. 7886-7892 CrossRef
  40. Tikoo, K, Kumar, P, Gupta, J (2009) Rosiglitazone synergizes anticancer activity of cisplatin and reduces its nephrotoxicity in 7, 12-dimethyl benz{a}anthracene (DMBA) induced breast cancer rats. BMC Cancer 9: pp. 107 CrossRef
  41. Yee, LD, Williams, N, Wen, P, Young, DC, Lester, J, Johnson, MV, Farrar, WB, Walker, MJ, Povoski, SP, Suster, S (2007) Pilot study of rosiglitazone therapy in women with breast cancer: effects of short-term therapy on tumor tissue and serum markers. Clin Cancer Res 13: pp. 246-252 CrossRef
  42. Musgrove, EA, Lee, CS, Sutherland, RL (1991) Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor alpha, epidermal growth factor receptor, c-fos, and c-myc genes. Mol Cell Biol 11: pp. 5032-5043
  43. Skildum, A, Faivre, E, Lange, CA (2005) Progesterone receptors induce cell cycle progression via activation of mitogen-activated protein kinases. Mol Endocrinol 19: pp. 327-339 CrossRef
  44. Lu, S, Becker, KA, Hagen, MJ, Yan, H, Roberts, AL, Mathews, LA, Schneider, SS, Siegelmann, HT, MacBeth, KJ, Tirrell, SM (2008) Transcriptional responses to estrogen and progesterone in mammary gland identify networks regulating p53 activity. Endocrinology 149: pp. 4809-4820 CrossRef
  45. Obr, AE, Edwards, DP (2012) The biology of progesterone receptor in the normal mammary gland and in breast cancer. Mol Cell Endocrinol 357: pp. 4-17 CrossRef
  46. Hilton, HN, Kalyuga, M, Cowley, MJ, Alles, MC, Lee, HJ, Caldon, CE, Blazek, K, Kaplan, W, Musgrove, EA, Daly, RJ (2010) The antiproliferative effects of progestins in T47D breast cancer cells are tempered by progestin induction of the ETS transcription factor Elf5. Mol Endocrinol 24: pp. 1380-1392 CrossRef
  47. Lehtonen, E, Stefanovic, V, Saraga-Babic, M (1995) Changes in the expression of intermediate filaments and desmoplakins during development of human notochord. Differentiation 59: pp. 43-49 CrossRef
  48. Kester, HA, van der Leede, BM, van der Saag, PT, van der Burg, B (1997) Novel progesterone target genes identified by an improved differential display technique suggest that progestin-induced growth inhibition of breast cancer cells coincides with enhancement of differentiation. J Biol Chem 272: pp. 16637-16643 CrossRef
  49. Chalbos, D, Escot, C, Joyeux, C, Tissot-Carayon, MJ, Pages, A, Rochefort, H (1990) Expression of the progestin-induced fatty acid synthetase in benign mastopathies and breast cancer as measured by RNA in situ hybridization. J Natl Cancer Inst 82: pp. 602-606 CrossRef
  50. Chalbos, D, Joyeux, C, Galtier, F, Escot, C, Chambon, M, Maudelonde, T, Rochefort, H (1990) Regulation of fatty acid synthetase by progesterone in normal and tumoral human mammary glands. Rev Esp Fisiol 46: pp. 43-46
  51. Wasserman, L, Nordenberg, J, Beery, E, Deutsch, AA, Novogrodsky, A (1987) Differential effects of sodium butyrate and dimethylsulfoxide on gamma-glutamyl transpeptidase and alkaline phosphatase activities in MCF-7 breast cancer cells. Exp Cell Biol 55: pp. 188-193
  52. Leo, JC, Wang, SM, Guo, CH, Aw, SE, Zhao, Y, Li, JM, Hui, KM, Lin, VC (2005) Gene regulation profile reveals consistent anticancer properties of progesterone in hormone-independent breast cancer cells transfected with progesterone receptor. Int J Cancer 117: pp. 561-568 CrossRef
  53. Shibata, H, Spencer, TE, Onate, SA, Jenster, G, Tsai, SY, Tsai, MJ, O鈥橫alley, BW (1997) Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action. Recent Prog Horm Res 52: pp. 141-164
  54. Pagliuca, A, Gallo, P, Lania, L (2000) Differential role for Sp1/Sp3 transcription factors in the regulation of the promoter activity of multiple cyclin-dependent kinase inhibitor genes. J Cell Biochem 76: pp. 360-367 CrossRef
  55. Xiao, H, Hasegawa, T, Isobe, K (2000) p300 collaborates with Sp1 and Sp3 in p21(waf1/cip1) promoter activation induced by histone deacetylase inhibitor. J Biol Chem 275: pp. 1371-1376 CrossRef
  56. Mikita, T, Daniel, C, Wu, P, Schindler, U (1998) Mutational analysis of the STAT6 SH2 domain. J Biol Chem 273: pp. 17634-17642 CrossRef
  57. Goenka, S, Youn, J, Dzurek, LM, Schindler, U, Yu-Lee, LY, Boothby, M (1999) Paired Stat6 C-terminal transcription activation domains required both for inhibition of an IFN-responsive promoter and trans-activation. J Immunol 163: pp. 4663-4672
  58. Zhou, X, Jiang, Y, Lu, L, Ding, Q, Jiao, Z, Zhou, Y, Xin, L, Chou, KY (2007) MHC class II transactivator represses human IL-4 gene transcription by interruption of promoter binding with CBP/p300, STAT6 and NFAT1 via histone hypoacetylation. Immunology 122: pp. 476-485 CrossRef
  59. Shankaranarayanan, P, Chaitidis, P, Kuhn, H, Nigam, S (2001) Acetylation by histone acetyltransferase CREB-binding protein/p300 of STAT6 is required for transcriptional activation of the 15-lipoxygenase-1 gene. J Biol Chem 276: pp. 42753-42760 CrossRef
  60. Pardali, K, Kurisaki, A, Moren, A, ten Dijke, P, Kardassis, D, Moustakas, A (2000) Role of Smad proteins and transcription factor Sp1 in p21(Waf1/Cip1) regulation by transforming growth factor-beta. J Biol Chem 275: pp. 29244-29256 CrossRef
  61. Ma, Y, Katiyar, P, Jones, LP, Fan, S, Zhang, Y, Furth, PA, Rosen, EM (2006) The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells. Mol Endocrinol 20: pp. 14-34 CrossRef
  62. Noruzinia, M, Coupier, I, Pujol, P (2005) Is BRCA1/BRCA2-related breast carcinogenesis estrogen dependent?. Cancer 104: pp. 1567-1574 CrossRef
  63. Inoue, T, Kamiyama, J, Sakai, T (1999) Sp1 and NF-Y synergistically mediate the effect of vitamin D(3) in the p27(Kip1) gene promoter that lacks vitamin D response elements. J Biol Chem 274: pp. 32309-32317 CrossRef
  64. Lee, TH, Chang, HC, Chuang, LY, Hung, WC (2003) Involvement of PKA and Sp1 in the induction of p27(Kip1) by tamoxifen. Biochem Pharmacol 66: pp. 371-377 CrossRef
  65. Waby, JS, Chirakkal, H, Yu, C, Griffiths, GJ, Benson, RS, Bingle, CD, Corfe, BM (2010) Sp1 acetylation is associated with loss of DNA binding at promoters associated with cell cycle arrest and cell death in a colon cell line. Mol Cancer 9: pp. 275 CrossRef
  66. Deniaud, E, Baguet, J, Chalard, R, Blanquier, B, Brinza, L, Meunier, J, Michallet, MC, Laugraud, A, Ah-Soon, C, Wierinckx, A (2009) Overexpression of transcription factor Sp1 leads to gene expression perturbations and cell cycle inhibition. PLoS One 4: pp. e7035 CrossRef
  67. Caldon, CE, Sergio, CM, Schutte, J, Boersma, MN, Sutherland, RL, Carroll, JS, Musgrove, EA (2009) Estrogen regulation of cyclin E2 requires cyclin D1 but not c-Myc. Mol Cell Biol 29: pp. 4623-4639 CrossRef
  68. Dai, D, Wolf, DM, Litman, ES, White, MJ, Leslie, KK (2002) Progesterone inhibits human endometrial cancer cell growth and invasiveness: down-regulation of cellular adhesion molecules through progesterone B receptors. Cancer Res 62: pp. 881-886
  69. Mommers, EC, Leonhart, AM, Falix, F, Michalides, R, Meijer, CJ, Baak, JP, Diest, PJ (2001) Similarity in expression of cell cycle proteins between in situ and invasive ductal breast lesions of same differentiation grade. J Pathol 194: pp. 327-333 CrossRef
  70. Said, TK, Moraes, RC, Singh, U, Kittrell, FS, Medina, D (2001) Cyclin-dependent kinase (cdk) inhibitors/cdk4/cdk2 complexes in early stages of mouse mammary preneoplasia. Cell Growth Differ 12: pp. 285-295
  71. Vorherr, H (1979) Pregnancy and lactation in relation to breast cancer risk. Semin Perinatol 3: pp. 299-311
  72. Medina, D (2004) Breast cancer: the protective effect of pregnancy. Clin Cancer Res 10: pp. 380S-384S CrossRef
  73. Narod SA: Hormone replacement therapy and the risk of breast cancer. / Nat Rev Clin Oncol 8(11):669鈥?76.
  74. Faber, A, Bouvy, ML, Loskamp, L, van de Berg, PB, Egberts, TC, de Jong-van den Berg, LT (2005) Dramatic change in prescribing of hormone replacement therapy in The Netherlands after publication of the Million Women Study: a follow-up study. Br J Clin Pharmacol 60: pp. 641-647 CrossRef
  75. Pasqualini, JR (2007) Progestins and breast cancer. Gynecol Endocrinol 23: pp. 32-41 CrossRef
  76. Eden, J (2003) Progestins and breast cancer. Am J Obstet Gynecol 188: pp. 1123-1131 CrossRef
  77. Sutherland, RL, Watts, CK, Musgrove, EA (1993) Cyclin gene expression and growth control in normal and neoplastic human breast epithelium. J Steroid Biochem Mol Biol 47: pp. 99-106 CrossRef
  78. Darzynkiewicz, Z, Gong, J, Juan, G, Ardelt, B, Traganos, F (1996) Cytometry of cyclin proteins. Cytometry 25: pp. 1-13 CrossRef
  79. Bulun, SE, Cheng, YH, Pavone, ME, Xue, Q, Attar, E, Trukhacheva, E, Tokunaga, H, Utsunomiya, H, Yin, P, Luo, X (2010) Estrogen receptor-beta, estrogen receptor-alpha, and progesterone resistance in endometriosis. Semin Reprod Med 28: pp. 36-43 CrossRef
  80. Bedard, PL, Freedman, OC, Howell, A, Clemons, M (2008) Overcoming endocrine resistance in breast cancer: are signal transduction inhibitors the answer?. Breast Cancer Res Treat 108: pp. 307-317 CrossRef
  81. Milde-Langosch, K, Loning, T, Bamberger, AM (2003) Expression of the CCAAT/enhancer-binding proteins C/EBPalpha, C/EBPbeta and C/EBPdelta in breast cancer: correlations with clinicopathologic parameters and cell-cycle regulatory proteins. Breast Cancer Res Treat 79: pp. 175-185 CrossRef
  82. Masciullo, V, Susini, T, Zamparelli, A, Bovicelli, A, Minimo, C, Massi, D, Taddei, G, Maggiano, N, De Iaco, P, Ceccaroni, M (2003) Frequent loss of expression of the cyclin-dependent kinase inhibitor p27(Kip1) in estrogen-related Endometrial adenocarcinomas. Clin Cancer Res 9: pp. 5332-5338
  83. Tsuchiya, A, Zhang, GJ, Kanno, M (1999) Prognostic impact of cyclin-dependent kinase inhibitor p27kip1 in node-positive breast cancer. J Surg Oncol 70: pp. 230-234 CrossRef
  84. Chu, JS, Huang, CS, Chang, KJ (1999) p27 expression as a prognostic factor of breast cancer in Taiwan. Cancer Lett 141: pp. 123-130 CrossRef
  85. Chiarle, R, Pagano, M, Inghirami, G (2001) The cyclin dependent kinase inhibitor p27 and its prognostic role in breast cancer. Breast Cancer Res 3: pp. 91-94 CrossRef
  86. Zhang, WJ, Li, BH, Yang, XZ, Li, PD, Yuan, Q, Liu, XH, Xu, SB, Zhang, Y, Yuan, J, Gerhard, GS (2008) IL-4-induced Stat6 activities affect apoptosis and gene expression in breast cancer cells. Cytokine 42: pp. 39-47 CrossRef
  87. Hartmann, S, Martin-Subero, JI, Gesk, S, Husken, J, Giefing, M, Nagel, I, Riemke, J, Chott, A, Klapper, W, Parrens, M (2008) Detection of genomic imbalances in microdissected Hodgkin and Reed-Sternberg cells of classical Hodgkin鈥檚 lymphoma by array-based comparative genomic hybridization. Haematologica 93: pp. 1318-1326 CrossRef
  88. Comprehensive genomic characterization defines human glioblastoma genes and core pathways / Nature 455(7216):1061鈥?068.
  89. Wikman, H, Nymark, P, Vayrynen, A, Jarmalaite, S, Kallioniemi, A, Salmenkivi, K, Vainio-Siukola, K, Husgafvel-Pursiainen, K, Knuutila, S, Wolf, M (2005) CDK4 is a probable target gene in a novel amplicon at 12q13.3-q14.1 in lung cancer. Genes Chromosomes Cancer 42: pp. 193-199 CrossRef
  90. de Marval PL, M, Macias, E, Conti, CJ, Rodriguez-Puebla, ML (2004) Enhanced malignant tumorigenesis in Cdk4 transgenic mice. Oncogene 23: pp. 1863-1873 CrossRef
  91. Ali, S, Buluwela, L, Coombes, RC (2011) Antiestrogens and their therapeutic applications in breast cancer and other diseases. Annu Rev Med 62: pp. 217-232 CrossRef
  92. Kremoser, C, Albers, M, Burris, TP, Deuschle, U, Koegl, M (2007) Panning for SNuRMs: using cofactor profiling for the rational discovery of selective nuclear receptor modulators. Drug Discov Today 12: pp. 860-869 CrossRef
  93. Chwalisz, K, Perez, MC, Demanno, D, Winkel, C, Schubert, G, Elger, W (2005) Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocr Rev 26: pp. 423-438 CrossRef
  94. Ahmad, N, Kumar, R (2011) Steroid hormone receptors in cancer development: a target for cancer therapeutics. Cancer Lett 300: pp. 1-9 CrossRef
  95. The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2407/14/10/prepub
  
• 刊物主题：Cancer Research; Oncology; Stem Cells; Animal Models; Internal Medicine;
• 出版者：BioMed Central
• ISSN：1471-2407

文摘

Background Progesterone is essential for the proliferation and differentiation of mammary gland epithelium. Studies of breast cancer cells have demonstrated a biphasic progesterone response consisting of an initial proliferative burst followed by sustained growth arrest. However, the transcriptional factors acting with the progesterone receptor (PR) to mediate the effects of progesterone on mammary cell growth and differentiation remain to be determined. Recently, it was demonstrated that signal transducer and activator of transcription 6 (Stat6) is a cell growth suppressor. Similar to progesterone-bound PR, Stat6 acts by inducing the expression of the G1 cyclin-dependent kinase inhibitors p21 and p27. The possible interaction between Stat6 and progesterone pathways in mammary cells was therefore investigated in the present study. Methods ChIP and luciferase were assayed to determine whether Stat6 induces p21 and p27 expression by recruitment at the proximal Sp1-binding sites of the gene promoters. Immunoprecipitation and Western blotting were performed to investigate the interaction between Stat6 and PR-B. The cellular DNA content and cell cycle distribution in breast cancer cells were analyzed by FACS. Results We found that Stat6 interacts with progesterone-activated PR in T47D cells. Stat6 synergizes with progesterone-bound PR to transactivate the p21 and p27 gene promoters at the proximal Sp1-binding sites. Moreover, Stat6 overexpression and knockdown, respectively, increased or prevented the induction of p21 and p27 gene expression by progesterone. Stat6 knockdown also abolished the inhibitory effects of progesterone on pRB phosphorylation, G1/S cell cycle progression, and cell proliferation. In addition, knockdown of Stat6 expression prevented the induction of breast cell differentiation markers, previously identified as progesterone target genes. Finally, Stat6 gene expression levels increased following progesterone treatment, indicating a positive auto-regulatory loop between PR and Stat6. Conclusions Taken together, these data identify Stat6 as a coactivator of PR mediating the growth-inhibitory and differentiation effects of progesterone on breast cancer cells.